Crown Bioscience Wins BioTech Breakthrough Award for Drug Development Innovation

San Diego, USA—December 10, 2024—Crown Bioscience, a global contract research organization (CRO) headquartered in San Diego, California in the United States, and a part of JSR Life Sciences and Japan-based JSR Corporation, is proud to be the recipient of the BioTech Breakthrough Award in the Biopharma category for its innovation in drug development. This prestigious award highlights the achievements of its OrganoidXplore™ screening platform in advancing preclinical and translational oncology research. OrganoidXplore has emerged as the leading organoid panel screening service by processing more than 100 oncology models in six weeks, significantly expediting the drug development process with its rapid, data-driven decision-making capabilities. Utilizing a comprehensive selection of Patient-Derived Organoids (PDO) and Patient-Derived Xenograft Organoids (PDXO), the platform delves into the diversity of cancer tumors to aid in the discovery of novel cancer treatments and to facilitate more personalized therapeutic approaches.

"The BioTech Breakthrough Award is a testament to our team's dedication and the innovative spirit that drives Crown Bioscience," said Leo Price, Senior Vice President of Corporate Innovation. OrganoidXplore is at the forefront of our efforts to empower scientific advancements and equip our clients with the insights needed for the development of future oncology treatments."

The platform focuses on stringent validation and quality control measures, including SNP verification and benchmarked standard of care controls included in each run to ensure the reliability and reproducibility of the data it delivers. Another unique aspect of OrganoidXplore is its integration within Crown Bioscience’s translational oncology service ecosystem. This enables customers to seamlessly advance their findings from OrganoidXplore to the next stage of their research. This comprehensive approach has won over the market and facilitated collaborative efforts globally, emphasizing OrganoidXplore as an essential tool in oncology research and drug development.

The BioTech Breakthrough Awards, recognized globally, aim to identify and celebrate the leading companies, platforms, and services in the life sciences and biotech industries. For a complete list of this year's winners, visit the BioTech Breakthrough Awards website.

About Crown Bioscience

Crown Bioscience, a JSR Life Sciences company, is a global Contract Research Organization (CRO) dedicated to improving human health through partnering with biotech and pharmaceutical companies that drive the discovery and development of oncology drugs. We exclusively offer preclinical tumor organoid services using the well-established Hubrecht Organoid Technology, with over 600 organoid models available spanning 22 cancer indications. In addition, we have developed the world’s largest commercially available PDX collection. Further committed to personalized medicine, our subsidiary, Indivumed Services, maintains an extensive biobank of liquid and tissue human biospecimens. Our focus on helping our customers develop novel therapies aims to ensure that patients receive the right treatment at the right time. Founded in 2006, we have 12 facilities across the US, Europe, and Asia. For more information, please visit www.crownbio.com

Media Inquiries:

Crown Bioscience

Sarah Martin-Tyrrell

pr@crownbio.com